Last edited by Tygogar
Tuesday, August 31, 2021 | History

3 edition of Cancer radioimmunotherapy found in the catalog.

Cancer radioimmunotherapy

Cancer radioimmunotherapy

present and future

by

  • 393 Want to read
  • 25 Currently reading

Published by Harwood Academic in Amsterdam, The Netherlands .
Written in English

    Subjects:
  • Cancer -- Radioimmunotherapy.,
  • Neoplasms -- radiotherapy,
  • Radioimmunotherapy -- trends

  • Edition Notes

    Includes bibliographical references and index.

    Statementedited by Pietro Riva.
    ContributionsRiva, Pietro.
    Classifications
    LC ClassificationsRC271.R26 C26 1999
    The Physical Object
    Paginationxviii, 510 p. :
    Number of Pages510
    ID Numbers
    Open LibraryOL21950089M
    ISBN 109057023091


Share this book
You might also like
Fluorite occurrences in Utah

Fluorite occurrences in Utah

Ethics - Theory and Practice

Ethics - Theory and Practice

How to stop killing yourself.

How to stop killing yourself.

The works of Daniel Defoe

The works of Daniel Defoe

[Heresiography

[Heresiography

history of the Tory Party 1640-1714

history of the Tory Party 1640-1714

The Johnstown area flood of 1977

The Johnstown area flood of 1977

The Tettigoniidae

The Tettigoniidae

Book of Aphrodisiacs

Book of Aphrodisiacs

bibliography of the Kings Book

bibliography of the Kings Book

A year in white

A year in white

1978 census of agriculture, preliminary report, Clarke County, Ala.

1978 census of agriculture, preliminary report, Clarke County, Ala.

Wills and post-death tax planning

Wills and post-death tax planning

Cooking for life

Cooking for life

Cancer radioimmunotherapy Download PDF EPUB FB2

Radioimmunotherapy (RIT) is the targeted delivery of radiation to disseminated cancer by monoclonal antibodies that bind to tumor-associated antigens. Development of monoclonal reagents has permitted more specific targeting, as well as large-scale production of conjugates for clinical trials.

The limited efficacy of unmodified monoclonal antibodies has prompted their use as carriers of Cited by: 1. Cancer Radioimmunotherapy: Present and Future [Riva, Pietro] on FREE shipping on qualifying offers. Cancer Radioimmunotherapy: Present and FutureCited by: 4. Reflecting the past 20 years of intense research in radioimmunotherapy, Cancer radioimmunotherapy book timely reference surveys an expansive breadth of topics on the evolving developments in radiation therapy.

Placed in the context of advances in cancer treatment, chapters progress systematically from basic principles and properties of radionuclides to detailed summaries ofAuthors: Paul G. Abrams, Alan R. Fritzberg. The authors offer the historical perspectives and prospects for the future for radioimmunotherapy of cancer.

The first radioimmunotherapy treatments, the development of human chorionic gonadotropin (hCG) hormone as a tumor specific antigen and the use of monoclonal.

Cancer Radioimmunotherapy: Present And Future|Pietro Riva, The White Chief of the Caffres|Alfred W. Drayson, Obscenity and Pornography: The Law Under the First Amendment (Legal Almanac Series)|Daniel S. Moretti, Coffee Planting in Southern India and Ceylon. |Edmund Charles P.

Hull. Cancer radioimmunotherapy book ductal adenocarcinoma (PDAC) has long been associated with low survival rates. A lack of accurate diagnostic tests and limited treatment options contribute to the poor prognosis of PDAC.

Radioimmunotherapy using α- or β-emitting radionuclides has been identified as a potential treatment for PDAC. By harnessing the cytotoxicity of α or β particles, radioimmunotherapy may overcome Cited by: 5. In book: Systemic Drug Delivery Strategies (pp) Authors: conclusion and future perspective of application of radioimmunotherapy in neurooncology cancer care.

FIGURE 1. Abscopal Effects and Out-of-Field Lesion Regression Induced by Radioimmunotherapy In recurrent or metastatic HNSCC, abscopal antitumor immunity is induced by RT of a pulmonary metastasis combined with systemic immune checkpoint blockade.

RT generates an in situ cancer vaccine which, in the presence of immune checkpoint inhibition. Cancer radioimmunotherapy book The modern era of radionuclide imaging and therapy is well into its seventh decade.

During this era, many national and international textbooks have been published in an attempt to educate not only the practitioners of our medical discipline, but also referring physicians and medical students. Some of the more recent large multic- tural texts, such as those by Ell and Ghambir, Sandler et al 35(1).

Novel Concepts in Radioimmunotherapy for Non-Hodgkin's Lymphoma Randomized Controlled Trial of Zevalin Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell NHL   Abstract. The therapeutic efficacy of radioimmunotherapy (RIT) of Re-labeled herceptin, which is a humanized anti-pHER2neu monoclonal antibody (mAb), was studied.

The nude mice bearing nasopharyngeal carcinoma (NPC) expressing HER2neu protooncogene were injected with Re-herceptin intratumorally and intravenously. Pancreatic cancer does not respond to a single-agent imatinib therapy. Consequently, multimodality treatments are contemplated.

Published data indicate that in colorectal cancer, imatinib and radioimmunotherapy synergize to delay tumor growth. In pancreatic cancer, the tumor response is additive. This disparity of outcomes merited further studies because interactions between these.

BACKGROUND. 90 Y ibritumomab tiuxetan is a radioimmunotherapeutic construct that is reported to be an effective treatment for patients with lymphoma. The aim of the current analysis was to evaluate retrospectively the efficacy and safety of 90 Y ibritumomab tiuxetan in patients with Richter syndrome (RS).

METHODS. Patients with histologically proven CDpositive RS and lymphoma. Radioimmunotherapy of solid tumors remains a challenge despite the tremendous success of 90Y ibritumomab tiuxetan (Zevalin) and I Tositumomab (Bexxar) in treating non-Hodgkins lymphoma.

For a variety of reasons, clinical trials of radiolabeled antibodies against solid tumors have not led to responses equivalent to those seen against lymphoma.

Radioimmunotherapy (RIT) potentially is an attractive treatment for radiosensitive early-stage solid tumors and as an adjuvant to cytoreductive surgery.

Topical administration of. Epithelial ovarian cancer (EOC) is known to produce carcinoembryonic antigen (CEA), and the plasma CEA level is frequently elevated in patients with advanced stage and bulk of tumor. This study reports the results of a phase I therapy trial with intravenously administered I-MN anti-CEA monoclonal antibody (MAb) in patients with EOC.

Methods. Immune cells within the tumor can act either to promote growth or rejection of tumor cells. The aim of the present study was to evaluate immune cell markers (number and localization) within the tumor before and during rejection due to radioimmunotherapy, to determine whether there is a change in markers related to rejection andor tolerance of the tumor cells.

The study was approved by the MD Anderson Cancer Center institutional review board, and all patients signed a written informed consent according to the institutional guidelines. The patients received an initial infusion of mgm 2 rituximab, followed immediately by a fixed dose of mCi of In 90 Y ibritumomab.

Radioimmunotherapy (RIT) is a targeted molecular therapy that bears upon radiobiological and immunological processes, without cross-resistance with other anti-cancer cytotoxic drugs.

To reduce toxicity associated with external γ-beam radiation, we investigated radioimmunotherapy with an anti-CD45 mAb labeled with the α-emitter, astatine ( At), as a conditioning regimen in dog leukocyte antigen-identical hematopoietic cell transplantation (HCT).

Dose-finding studies in 6 dogs treated with to μCikg At-labeled anti-CD45 mAb ( mgkg). Biomedical Research Collection - Mary Ann Liebert, Inc.publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in the most promising areas of biotechnology and regenerative medicine, biomedical research, clinical medicine and surgery, technology and engineering, law, integrative medicine, public health, and environmental studies.

The patients were treated between December and Mayall being followed up for 6 months or until relapse. At MAb treatment 29 patients had stage III disease. The other 3 patients were in complete remission following chemotherapy for stage IIIIV tumors.

{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"","frontPageModel":{"patentViewModel":{"ref":{"entityRefType. Fishpond United States, Radioactive Isotopes in Clinical Medicine and Research: Proceedings of the 22nd Badgastein Symposium (Advances in Pharmacological Sciences) by H Bergmann (Edited) A Kroiss (Edited)Buy.

Books online: Radioactive Isotopes in Clinical Medicine and Research: Proceedings of the 22nd Badgastein Symposium (Advances in Pharmacological Sciences),radiation and chemo for lung cancer.